MCID: SQM006
MIFTS: 60

Squamous Cell Carcinoma

Categories: Cancer diseases, Rare diseases, Skin diseases

Aliases & Classifications for Squamous Cell Carcinoma

MalaCards integrated aliases for Squamous Cell Carcinoma:

Name: Squamous Cell Carcinoma 12 75 53 37 29 6 15 17 72
Carcinoma, Squamous Cell 75 53 44
Epidermoid Carcinoma 12 75 53
Squamous Cell Cancer 12 55 15
Squamous Cell Carcinoma - Category 72
Malignant Squamous Cell Neoplasm 72
Squamous Cell Carcinoma of Skin 72
Malignant Squamous Cell Tumor 12
Squamous Cell Epithelioma 12
Squamous Cell Skin Cancer 53
Neoplasms, Squamous Cell 44
Carcinoma Squamous Cell 55
Squamous Carcinoma 12

Classifications:



External Ids:

Disease Ontology 12 DOID:1749
KEGG 37 H00040
NCIt 50 C2929
SNOMED-CT 68 28899001
UMLS 72 C0007137 C0553723 C0751688 more

Summaries for Squamous Cell Carcinoma

KEGG : 37
Non-melanoma skin cancer, i.e. basal cell carcinoma (BCC) and squamous cell carcinoma (SCC) are the most frequent tumors and their number is still increasing world- wide. Approximately 200000 cases of SCC develop per year, causing about 2000 deaths. Unlike BCCs, which have no known precursor lesions, SCCs can emerge from actinic keratoses. SCC in anogenital regions can be caused by oncogenic human papillomavirus (HPV) strains. As with BCC, risk for development of SCC is strongly influenced by the nature and dose of UV radiation and genetic backgrounds that regulate that interaction. Mutations in TP53 have been described in actinic keratoses, in situ SCC, and invasive SCC with UV signature lesions common, and a reported mutation rate as high as 45%. As with TP53, UV-induced mutations in HRAS and KRAS have also been characterized in both actinic keratoses and SCC. The reported frequency of RAS mutations in SCCs ranges from approximately 10% to almost 50%. Several recent studies have also reported mutations of p16 in up to 24% of SCCs.

MalaCards based summary : Squamous Cell Carcinoma, also known as carcinoma, squamous cell, is related to squamous cell carcinoma, head and neck and tongue squamous cell carcinoma. An important gene associated with Squamous Cell Carcinoma is DDR2 (Discoidin Domain Receptor Tyrosine Kinase 2), and among its related pathways/superpathways is LncRNA-mediated mechanisms of therapeutic resistance. The drugs Titanium dioxide and Ethanol have been mentioned in the context of this disorder. Affiliated tissues include lung, skin and lymph node.

Disease Ontology : 12 A carcinoma that derives from squamous epithelial cells.

NIH Rare Diseases : 53 Squamous cell carcinoma (SCC) is the second most common skin cancer. SCC most often affects individuals who are exposed to large amounts of sunlight. It is typically characterized by a red papule or plaque with a scaly or crusted surface; it may be suspected whenever a small, firm reddish-colored skin lesion, growth or bump appears on the skin, but it may also be a flat growth with a curly and crusted surface. Most often these growths are located on the face, ears, neck, hands and/or arms, but they may occur on the lips, mouth, tongue, genitalia or other area. The most common causes of SCC are radiation from the sun and arsenic exposure. With appropriate treatment, it is usually curable.

Wikipedia : 75 Squamous cell carcinomas (SCCs), also known as epidermoid carcinomas, comprise a number of different... more...

Related Diseases for Squamous Cell Carcinoma

Diseases related to Squamous Cell Carcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 1810)
# Related Disease Score Top Affiliating Genes
1 squamous cell carcinoma, head and neck 35.1 SPRY4-IT1 MIR205 HOTAIR H19 C5orf66-AS1
2 tongue squamous cell carcinoma 34.8 UCA1 MALAT1 LINC01503
3 esophagus squamous cell carcinoma 34.7 LINC01233 HOTAIR
4 laryngeal squamous cell carcinoma 34.7 MALAT1 HOTAIR H19 CDKN2B-AS1
5 oral squamous cell carcinoma 34.7 UCA1 TUG1 MALAT1 HOTAIR H19 CCAT2
6 lung squamous cell carcinoma 34.4 TUG1 SOX2-OT CCAT2
7 nasopharyngeal carcinoma 33.7 MALAT1 HOTAIR H19 CDKN2B-AS1 CASC9
8 esophageal cancer 33.4 UCA1 PCAT1 MIR205 MALAT1 HOTAIR H19
9 lung cancer susceptibility 3 31.8 TUG1 MALAT1 HOTAIR H19
10 prostate cancer 31.7 UCA1 TUG1 SPRY4-IT1 PCAT1 MIR205 MALAT1
11 thyroid cancer, nonmedullary, 1 31.6 MALAT1 HOTAIR H19
12 gastric cardia adenocarcinoma 31.5 HOTAIR H19 C5orf66-AS1
13 small cell cancer of the lung 31.5 TUG1 MALAT1 HOTAIR CCAT2
14 bladder cancer 31.3 UCA1 TUG1 TINCR SPRY4-IT1 PCAT1 MIR205
15 lung cancer 31.3 UCA1 TUG1 TINCR SPRY4-IT1 SOX2-OT RIOX2
16 renal cell carcinoma, nonpapillary 31.2 UCA1 TUG1 MALAT1 HOTAIR H19
17 cervical cancer 31.1 UCA1 TUG1 SPRY4-IT1 PCAT1 MALAT1 HOTAIR
18 glioblastoma 31.0 TUG1 PCAT1 MALAT1 HOTAIR H19
19 leukemia, acute myeloid 31.0 UCA1 TUG1 MALAT1 HOTAIR CDKN2B-AS1
20 kidney cancer 31.0 MALAT1 HOTAIR H19
21 gallbladder cancer 30.9 UCA1 TUG1 MALAT1 HOTAIR H19 CDKN2B-AS1
22 melanoma 30.9 UCA1 SPRY4-IT1 SOX2-OT MIR205 MALAT1 HOTAIR
23 bladder urothelial carcinoma 30.8 TUG1 MALAT1 HOTAIR
24 myeloma, multiple 30.8 UCA1 TUG1 PCAT1 MALAT1 HOTAIR H19
25 malignant glioma 30.8 TUG1 SPRY4-IT1 HOTAIR CDKN2B-AS1
26 pancreatic ductal adenocarcinoma 30.8 UCA1 MALAT1 HOTAIR H19
27 ovarian epithelial cancer 30.7 MALAT1 HOTAIR H19
28 pituitary adenoma 30.7 MALAT1 HOTAIR H19 CCAT2
29 pancreatic cancer 30.6 UCA1 TUG1 SPRY4-IT1 MIR205 MALAT1 HOTAIR
30 glioma 30.4 UCA1 SPRY4-IT1 MALAT1 HOTAIR H19 CDKN2B-AS1
31 leukemia, chronic myeloid 30.4 UCA1 HOTAIR H19
32 breast cancer 30.3 UCA1 TUG1 SPRY4-IT1 SOX2-OT MIR205 MALAT1
33 prostatic hyperplasia, benign 30.3 UCA1 CDKN2B-AS1
34 cholangiocarcinoma 30.2 UCA1 TUG1 SPRY4-IT1 SOX2-OT PCAT1 MALAT1
35 pre-eclampsia 30.2 TUG1 SPRY4-IT1 MALAT1 HOTAIR H19
36 ovarian cancer 30.2 UCA1 TUG1 SPRY4-IT1 SOX2-OT MALAT1 HOTAIR
37 osteogenic sarcoma 30.1 UCA1 TUG1 SOX2-OT PCAT1 MALAT1 HOTAIR
38 colorectal cancer 29.8 UCA1 TUG1 TINCR SPRY4-IT1 SOX2-OT PCAT1
39 hepatocellular carcinoma 29.7 UCA1 TUG1 SPRY4-IT1 SOX2-OT RIOX2 PCAT1
40 gastric cancer 29.3 UCA1 TUG1 TINCR SPRY4-IT1 SOX2-OT RIOX2
41 palmoplantar hyperkeratosis with squamous cell carcinoma of skin and 46,xx sex reversal 12.8
42 gastric squamous cell carcinoma 12.8
43 basaloid squamous cell carcinoma 12.8
44 rectum squamous cell carcinoma 12.8
45 keratinizing squamous cell carcinoma 12.7
46 gallbladder squamous cell carcinoma 12.7
47 colon squamous cell carcinoma 12.7
48 adenoid squamous cell carcinoma 12.7
49 maxillary sinus squamous cell carcinoma 12.7
50 renal pelvis squamous cell carcinoma 12.7

Graphical network of the top 20 diseases related to Squamous Cell Carcinoma:



Diseases related to Squamous Cell Carcinoma

Symptoms & Phenotypes for Squamous Cell Carcinoma

Drugs & Therapeutics for Squamous Cell Carcinoma

Drugs for Squamous Cell Carcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 649)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Titanium dioxide Approved Phase 4 13463-67-7
2
Ethanol Approved Phase 4 64-17-5 702
3
Triamcinolone Approved, Vet_approved Phase 4 124-94-7 31307
4
Cevimeline Approved Phase 4 107233-08-9 25137844 83898
5
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 4 437-38-7 3345
6
Raltitrexed Approved, Investigational Phase 4 112887-68-0 104758
7 Hematinics Phase 4
8 Epoetin alfa Phase 4 113427-24-0
9 Narcotics Phase 4
10 Analgesics, Opioid Phase 4
11 Cholinergic Agents Phase 4
12 Omega 3 Fatty Acid Phase 4
13 arginine Phase 4
14 triamcinolone acetonide Phase 4
15 Triamcinolone hexacetonide Phase 4
16 Triamcinolone diacetate Phase 4
17 Fibrin Tissue Adhesive Phase 4
18 Anesthetics, Intravenous Phase 4
19 Adjuvants, Anesthesia Phase 4
20 Anesthetics, General Phase 4
21 Muscarinic Agonists Phase 4
22
Apatinib Phase 4 811803-05-1
23
Epirubicin Approved Phase 3 56420-45-2 41867
24
Gabapentin Approved, Investigational Phase 3 60142-96-3 3446
25
Bleomycin Approved, Investigational Phase 3 11056-06-7 5360373
26
Lapatinib Approved, Investigational Phase 3 388082-78-8, 231277-92-2 208908 9941095
27
Tocopherol Approved, Investigational Phase 3 1406-66-2, 54-28-4 14986
28
Isotretinoin Approved Phase 3 4759-48-2 5282379 5538
29
Doxycycline Approved, Investigational, Vet_approved Phase 3 564-25-0 54671203
30
Minocycline Approved, Investigational Phase 3 10118-90-8 5281021
31
Dapsone Approved, Investigational Phase 3 80-08-0 2955
32
Ifosfamide Approved Phase 3 3778-73-2 3690
33
Vinblastine Approved Phase 3 865-21-4 241903 13342
34
Promethazine Approved, Investigational Phase 3 60-87-7 4927
35
Histamine Approved, Investigational Phase 3 51-45-6 774
36
Diphenhydramine Approved, Investigational Phase 3 58-73-1, 147-24-0 3100
37
Topotecan Approved, Investigational Phase 3 123948-87-8, 119413-54-6 60700
38
Fluconazole Approved, Investigational Phase 2, Phase 3 86386-73-4 3365
39
Vincristine Approved, Investigational Phase 3 57-22-7, 2068-78-2 5978
40
Doxepin Approved, Investigational Phase 3 1668-19-5 667477 667468
41
Pilocarpine Approved, Investigational Phase 3 92-13-7, 54-71-7 5910
42
Dimethyl sulfoxide Approved, Vet_approved Phase 3 67-68-5 679
43
Mycophenolic acid Approved Phase 3 24280-93-1 446541
44
Vindesine Approved, Investigational Phase 3 59917-39-4, 53643-48-4 40839
45
Cisplatin Approved Phase 3 15663-27-1 84093 441203 2767
46
Ipilimumab Approved Phase 3 477202-00-9
47
Nedaplatin Approved, Investigational Phase 3 95734-82-0
48
Olaparib Approved Phase 3 763113-22-0 23725625
49
Cemiplimab Approved, Investigational Phase 3 1801342-60-8
50
Talazoparib Approved, Investigational Phase 2, Phase 3 1207456-01-6 135565082

Interventional clinical trials:

(show top 50) (show all 2575)
# Name Status NCT ID Phase Drugs
1 A Double-Blind, Placebo-Controlled, Randomized Clinical Trial of Sodium Glycididazole in Concurrent Radiochemotherapy for the Treatment of Thoracic Esophageal Squamous Carcinoma Unknown status NCT00642239 Phase 4 placebo;Sodium Glycididazole
2 Endostar First-line Treatment of Advanced Non-small Cell Lung Squamous Carcinoma Based on Chemotherapy for Advanced Non-small Cell Lung Squamous Carcinoma Patients:a Randomized Controlled,Open, Multicenter Clinical Study Unknown status NCT02513342 Phase 4 Docetaxel;Cisplatin
3 Mometasone Furoate Cream Reduces Acute Radiation Dermatitis in Head and Neck Squamous Cell Carcinomas' Patients Receiving Radiation Therapy Unknown status NCT02495064 Phase 4 Mometasone Furoate Cream
4 Randomized Phase IV Trial to Compare Cetuximab With Concomitant Radiation Therapy With Concomitant Mitomycin-C and 5-Fluorouracil With Radiation Therapy for Locally Advanced Squamous Cell Carcinomas of the Head and Neck Unknown status NCT02015650 Phase 4 Cetuximab;Mitomycin-C/ 5-Fluorouracil
5 Skin Changes in Head and Neck Cancer During Immuno-(Chemo-) And Radiotherapy With Erbitux® Unknown status NCT01553032 Phase 4 Erbitux®
6 An Investigator-Initiated Study to Assess the Safety and Efficacy of Imiquimod 3.75% Cream When Used After Cryotherapy in the Treatment of Hypertrophic Actinic Keratoses (AK) on Dorsal Hands and Forearms Unknown status NCT01229319 Phase 4 Cryotherapy alone to Left arm plus cryotherapy + imiquimod to Right arm;Cryotherapy alone to Left arm plus cryotherapy + imiquimod to Right arm
7 Comparison Between Two Regimens of Chemotherapy Concurrent With Radiotherapy in Locally Advanced Head and Neck Cancer Completed NCT03998696 Phase 4 Cisplatin 40 mg/m2;Cisplatin 100 mg/m2
8 Nedaplatin (Jiebaishu®) and Docetaxel in Comparison With Cisplatin and Docetaxel Regimen for the First Line Treatment of Advanced Squamous Cell Carcinoma of Lung(IIIB/IV): Randomized, Controlled, Multicentre Study Completed NCT02088515 Phase 4 Nedaplatin;Cisplatin;Docetaxel
9 Phase IV Trial to Use Stereotactic Body Radiotherapy for Head and Neck Tumors Completed NCT01344356 Phase 4
10 CSP #562 - The VA Keratinocyte Carcinoma Chemoprevention Trial Completed NCT00847912 Phase 4 5-fluorouracil;Placebo, vehicle control
11 Can Fibrin Sealant be Used to Reduce Post-operative Drainage Following Lymph Node Dissection: a Prospective Randomised Double Blind Trial. Completed NCT00324272 Phase 4 Fibrin Sealant (Tisseel) used in the Experimental Arm.
12 An Investigator-Initiated,Multicenter,Randomized,Double-Blind Placebo-Controlled Design Study to Assess the Effectiveness of CeviMeline to Improve OraL Health in Patients With XErostomia Secondary to Radiation Therapy for Treatment of Head and Neck Squamous Cell Carcinoma Completed NCT00466388 Phase 4 Cevimeline
13 A Clinical Trial of ALA Photodynamic Therapy for Treatment of Actinic Cheilitis in Patients With Squamous Cell Carcinoma of the Lip. Completed NCT00868088 Phase 4
14 Safety and Efficacy of Nab-paclitaxel (Abraxane) in Combination With Carboplatin as First Line Treatment in Elderly Subjects With Advance Non-Small Cell Lung Cancer (NSCLC): A Phase IV, Randomized, Open-Label, Multicenter Study (Abound.70+) Completed NCT02151149 Phase 4 nab-paclitaxel;Carboplatin
15 Phase IV Clinical Study Evaluating The Efficacy of Chemoradiotherapy Following Neoadjuvant Treatment With Docetaxel and Cisplatin in Indifferentiated and Non-keratinized Squamous Cell Carcinoma of Nasopharynx Completed NCT00772681 Phase 4 docetaxel and cisplatin
16 A Phase II Trial Evaluating Irinotecan and Capecitabine in Patients With Relapsed/Refractory Upper Gastrointestinal Tumours Completed NCT00220168 Phase 4 Irinotecan, Capecitabine
17 Long-term Effects of Aldara® 5% Cream and Solaraze® 3% Gel in the Treatment of Actinic Keratoses on the Face or Scalp With Respect to the Risk of Progression to In-situ and Invasive Squamous Cell Carcinoma Completed NCT01453179 Phase 4 Imiquimod;Diclofenac
18 Evaluation of Analgesic Efficacy of Transmucosal Fentanyl for Breakthrough Pain Caused by Interventional Gastrostomy Completed NCT02869321 Phase 4 Fentanyl;Morphine Sulfate;Fentanyl placebo;Morphine Sulfate placebo
19 An Open-Label Study Using the MedPulser Electroporation System to Treat Cutaneous and Subcutaneous Foci of Cancer Completed NCT00198276 Phase 4
20 Gene Expression in Renal Transplant Patients With Field Actinic Keratosis Undergoing Metvix® PDT Completed NCT01000636 Phase 4
21 Comparison of Two Immunomodulatory Formulas on the Number of Postoperative Infections in Oropharyngeal and Maxillofacial Cancer Patients Eligible Surgery Completed NCT02622880 Phase 4
22 Safety and Efficacy of Ingenol Mebutate Gel 0.015% for Treatment of Actinic Keratosis on the Face in Solid Organ Transplant Recipients Completed NCT02866695 Phase 4 ingenol mebutate gel 0.015%
23 Management Of Anemia Under RadioChemotherapy (MARCH): An Open, Randomized Multicenter Study Of The Effect Of NeoRecormon On Treatment Outcome In Patients With Advanced Cervical Cancer Stage IIB -IVA Treated With Primary Simultaneous Radiochemotherapy (Radiotherapy Plus Cisplatin) Completed NCT00046969 Phase 4 cisplatin
24 A Multi-center, OPen, InvEstigator Initiated Phase IV Clinical TRial to Evaluate the Efficacy and SaFety of Ingenol Mebutate Gel 0.015% on Face and Scalp & 0.05% on Trunk and Extremities in KorEan Patient With ACtinic KeraTosis (PERFECT) Completed NCT02716714 Phase 4 ingenol mebutate gel 0.015%;ingenol mebutate gel 0.05%
25 A Randomized, Double-blind Study to Evaluate the Efficacy of MuGard Mucoadhesive Oral Wound Rinse for the Amelioration of Oral Mucositis in Subjects Receiving Chemoradiation Therapy for the Treatment of Cancers of the Head and Neck Completed NCT01283906 Phase 4
26 Ablation of Gastric Dysplastic Mucosa by a Novel Endoscopic Radiofrequency Device. Completed NCT01523912 Phase 4
27 Treatment of AKs With Daylight-PDT: Comparing Two Photosensitizers (BF-200 ALA and MAL) Completed NCT01893203 Phase 4 BF-200 ALA cream;MAL cream
28 A Comparison of Polyglactin 910 and Chromic Gut Suture in the Closure of Punch Biopsy Sites Completed NCT01722994 Phase 4
29 Radiotherapy Combine With Raltitrexed Versus Radiotherapy Alone in Older Patients With Head and Neck Squamous Cell Carcinoma: a Prospective Randomized Controlled Trial Recruiting NCT03196843 Phase 4 Raltitrexed
30 Topical Ingenol Mebutate Versus 5% 5-fluorouracil Versus 5% Imiquimod Versus Photodynamic Therapy in Treatment of Actinic Keratosis: a Multi-centre Randomized Efficacy and Cost-effectiveness Study Active, not recruiting NCT02281682 Phase 4 Imiquimod;5-fluorouracil;Ingenol mebutate
31 A Multicenter, Randomized, Open-label, Parallel-group Study of Paclitaxel Liposome Injection and Cisplatin Compared With Gemcitabine and Carboplatin as First-line Therapy in Advanced Squamous Cell Carcinoma of Lung Not yet recruiting NCT02996214 Phase 4 Paclitaxel Liposome;Gemcitabine;Cisplatin
32 Apatinib Mesylate Was Used in the Treament of Patients With Advanced Lung Squamous Cell Carcinoma of the Third Line and Above Not yet recruiting NCT03725423 Phase 4 Apatinib
33 Multicenter Comparative of Toxicity and Effectiveness of Lobaplation or Cisplatin Based Adjuvant Chemotherapy in Esophageal Carcinoma Not yet recruiting NCT03413436 Phase 4 Lobaplatin;Cisplatin
34 Acitretin Plasma Levels Under Hemodialysis Withdrawn NCT00488384 Phase 4 Chemopreventive application (Acitretin)
35 Radiotherapy Dose Escalation in Locally Advanced Squamous Cell Carcinoma of the Larynx or Hypopharynx Withdrawn NCT03388931 Phase 4
36 Anal Dysplasia Study of Men Who Have Sex With Men Living With HIV Withdrawn NCT01663558 Phase 4 imiquimod
37 A Multicenter Phase Ⅲ Trial of Cisplatin Plus Raltitrexed or 5-fluorouracil in Concurrence With Intensity-modulated Radiotherapy (IMRT) for the Treatment of Locoregionally Advanced Head and Neck Squamous Cell Cancer Unknown status NCT02485548 Phase 3 Raltitrexed;5-fluorouracil;Cisplatin
38 Effectiveness and Safety of INGN 201 in Combination With Chemotherapy Versus Chemotherapy Alone Unknown status NCT00041626 Phase 3
39 Study to Compare the Overall Survival of Patients Receiving INGN 201 (Study Drug) With Patients Receiving Methotrexate Unknown status NCT00041613 Phase 3
40 An Open, Multicenter, Randomized Phase III Clinical Study on Cisplatin Combined With S-1 or Paclitaxel as First-line Treatment for Metastatic Esophageal Squamous Cell Carcinoma Unknown status NCT02677597 Phase 3 Cisplatin Combined With S-1;Cisplatin Combined With Paclitaxel
41 Controlled Randomized Trial to Evaluate Efficacy of Adjuvant Chemotherapy Between S-1 and UFT for Locally Advanced Squamous Cell Carcinoma of the Head and Neck: Phase III Study Unknown status NCT00336947 Phase 3 tegafur-gimeracil-oteracil potassium;tegafur-uracil
42 A RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED STUDY TO EVALUATE THE EFFECT OF CISPLATIN/EPINEPHRINE INJECTABLE GEL (PRODUCT MPI 5010) WHEN ADMINISTERED INTRATUMORALLY FOR ACHIEVEMENT OF TREATMENT GOALS IN RECURRENT OR REFRACTORY SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK Unknown status NCT00002659 Phase 3 cisplatin-e therapeutic implant
43 Is Elective Nodal Irradiation (ENI) Necessary For Patients With Thoracic Esophageal Squamous Cell Carcinoma Who Undergo Esophagectomy And With Pathological Stage Of T1-2,N+,M0 -- A Randomized Phase Ⅲ Trial Unknown status NCT01398449 Phase 3
44 A Randomized Phase III Study: Paclitaxel Plus Radiation Therapy With or Without Erlotinib in Treating Patients With Esophageal Squamous Carcinoma Unknown status NCT01752205 Phase 3 Paclitaxel;Erlotinib
45 An Prospective, Multicenter, Double-blind, Randomized, Controlled Clinical Study of Nimotuzumab Combined With Paclitaxel and Cisplatin as First-line Treatment of Metastatic Esophageal Squamous Cell Carcinomas Unknown status NCT02611700 Phase 3 Nimotuzumab;Paclitaxel;Cisplatin;Placebo
46 Determination of Epidermal Growth Factor Receptor-inhibitor (Cetuximab) Versus Standard Chemotherapy (Cisplatin) Early And Late Toxicity Events in Human Papillomavirus-positive Oropharyngeal Squamous Cell Carcinoma Unknown status NCT01874171 Phase 3 Cisplatin;Cetuximab
47 Chemoprevention of Esophageal Squamous Cell Carcinoma With Aspirin and Tea Polyphenols: a Randomized Controlled Trial. Unknown status NCT01496521 Phase 3 Aspirin
48 A Randomized Phase II Trial Evaluating The Addition Of Nimotuzumab To Chemoradiation For Patients With Esophageal Squamous Cell Carcinoma After Radical Esophagectomy Who Suffer With Lymph Nodes Recurrence Unknown status NCT01402180 Phase 2, Phase 3 chemotherapy;chemotherapy
49 Relationship Between Changes in Body Composition and Supplementation With EPA in Patients Diagnosed With Squamous Cell Carcinoma of Head and Neck Locally Advanced (Stage III-IVb) Unknown status NCT02715596 Phase 3
50 RANDOMIZED TRIAL OF NEOADJUVANT CHEMOTHERAPY AND SURGERY +/- RADIOTHERAPY VERSUS SURGEERY +/- RADIOTHERAPY IN OPERABLE SQUAMOUS CELL CARCINOMA OF THE ORAL CAVITY Unknown status NCT00002747 Phase 3 cisplatin;fluorouracil

Search NIH Clinical Center for Squamous Cell Carcinoma

Inferred drug relations via UMLS 72 / NDF-RT 51 :


Afatinib
afatinib dimaleate
Aminolevulinic acid
pembrolizumab
Technetium Tc-99m tilmanocept

Cochrane evidence based reviews: carcinoma, squamous cell

Genetic Tests for Squamous Cell Carcinoma

Genetic tests related to Squamous Cell Carcinoma:

# Genetic test Affiliating Genes
1 Squamous Cell Carcinoma 29

Anatomical Context for Squamous Cell Carcinoma

MalaCards organs/tissues related to Squamous Cell Carcinoma:

41
Lung, Skin, Lymph Node, Cervix, Tongue, Breast, Endothelial

Publications for Squamous Cell Carcinoma

Articles related to Squamous Cell Carcinoma:

(show top 50) (show all 36221)
# Title Authors PMID Year
1
Expression of CC-chemokine receptor 7 (CCR7) and CXC-chemokine receptor 4 (CXCR4) in head and neck squamous cell carcinoma. 9 38
20036791 2010
2
Expression of cyclooxygenase-2 and microsomal prostagalandin E synthase-1 in head and neck squamous cell carcinoma. 9 38
20034753 2010
3
Nerve growth factor and tyrosine kinase A receptor in oral squamous cell carcinoma: is there an association with perineural invasion? 9 38
20363547 2010
4
Tumor-related protein, the squamous cell carcinoma antigen binds to the intracellular protein carbonyl reductase. 9 38
20428762 2010
5
Expression and mutation analysis of her2 in head and neck squamous cell carcinoma. 9 38
20014947 2010
6
EGFR targeting drugs in the treatment of head and neck squamous cell carcinoma. 9 38
20415599 2010
7
Downregulation of N-cadherin expression inhibits invasiveness, arrests cell cycle and induces cell apoptosis in esophageal squamous cell carcinoma. 9 38
20014942 2010
8
Phase II prospective trial of gefitinib given concurrently with cisplatin and radiotherapy in patients with locally advanced head and neck cancer. 9 38
20470671 2010
9
Carrier cell-mediated cell lysis of squamous cell carcinoma cells by squamous cell carcinoma antigen 1 promoter-driven oncolytic adenovirus. 9 38
20527047 2010
10
Potential role of HDAC inhibitors in cancer therapy: insights into oral squamous cell carcinoma. 9 38
20207580 2010
11
Decreased GRP78 protein expression is a potential prognostic marker of oral squamous cell carcinoma in Taiwan. 9 38
20497865 2010
12
Impact of podoplanin expression in oral squamous cell carcinoma: clinical and histopathologic correlations. 9 38
20393745 2010
13
Clinical significance of EGFR, Her-2 and EGF in oral squamous cell carcinoma: a case control study. 9 38
20429940 2010
14
Cobalt chloride stimulates phosphoinositide 3-kinase/Akt signaling through the epidermal growth factor receptor in oral squamous cell carcinoma. 9 38
20506627 2010
15
Co-expression of Hif1alpha and CAIX is associated with poor prognosis in oral squamous cell carcinoma patients. 9 38
19780905 2010
16
Minichromosome maintenance-7 and geminin are reliable prognostic markers in patients with oral squamous cell carcinoma: immunohistochemical study. 9 38
20136698 2010
17
Regulation of p63 isoforms by snail and slug transcription factors in human squamous cell carcinoma. 9 38
20150431 2010
18
VEGF-C contributes to head and neck squamous cell carcinoma growth and motility. 9 38
20227330 2010
19
Cetuximab-based immunotherapy and radioimmunotherapy of head and neck squamous cell carcinoma. 9 38
20215534 2010
20
Vimentin expression of esophageal squamous cell carcinoma and its aggressive potential for lymph node metastasis. 9 38
20460738 2010
21
The predictive value of genes of the TGF-beta1 pathway in multimodally treated squamous cell carcinoma of the esophagus. 9 38
20012971 2010
22
TrkB induces EMT and has a key role in invasion of head and neck squamous cell carcinoma. 9 38
20101235 2010
23
mTOR inhibitor rapamycin alone or combined with cisplatin inhibits growth of esophageal squamous cell carcinoma in nude mice. 9 38
19853373 2010
24
Expression of nucleostemin, epidermal growth factor and epidermal growth factor receptor in human esophageal squamous cell carcinoma tissues. 9 38
19823871 2010
25
Prediction of CCND1 amplification using plasma DNA as a prognostic marker in oesophageal squamous cell carcinoma. 9 38
20389301 2010
26
p16INK4a hypermethylation and p53, p16 and MDM2 protein expression in esophageal squamous cell carcinoma. 9 38
20388212 2010
27
Fatty-acid-binding protein 5 promotes cell proliferation and invasion in oral squamous cell carcinoma. 9 38
20040021 2010
28
GLUT1 and GLUT3 as potential prognostic markers for Oral Squamous Cell Carcinoma. 9 38
20428049 2010
29
Clinical relevance of thymidylate synthase (TS) activity for S-1-based chemotherapy in squamous cell carcinoma of the oral cavity. 9 38
19576666 2010
30
BIIB021, a novel Hsp90 inhibitor, sensitizes head and neck squamous cell carcinoma to radiotherapy. 9 38
19662650 2010
31
Differentiated vulvar intraepithelial neoplasia contains Tp53 mutations and is genetically linked to vulvar squamous cell carcinoma. 9 38
20062014 2010
32
Initiation of malignancy by duodenal contents reflux and the role of ezrin in developing esophageal squamous cell carcinoma. 9 38
20128822 2010
33
LIMD1 is more frequently altered than RB1 in head and neck squamous cell carcinoma: clinical and prognostic implications. 9 38
20226061 2010
34
Expression and clinical significance of Ezrin and E-cadherin in esophageal squamous cell carcinoma. 9 38
20193117 2010
35
Aberrant changes of Wnt2/beta-catenin signaling pathway induced by sodium nitroprusside in human esophageal squamous cell carcinoma cell lines. 9 38
19857041 2010
36
SLP-2 overexpression is associated with tumour distant metastasis and poor prognosis in pulmonary squamous cell carcinoma. 9 38
19839737 2010
37
c-MYC depletion potentiates cisplatin-induced apoptosis in head and neck squamous cell carcinoma: involvement of TSP-1 up-regulation. 9 38
20008890 2010
38
Expression of Stat3 and Notch1 is associated with cisplatin resistance in head and neck squamous cell carcinoma. 9 38
20127005 2010
39
Expression and significance of tumor drug resistance related proteins and beta-catenin in esophageal squamous cell carcinoma. 9 38
20193114 2010
40
Lack of Fas-pathway gene mutations in primary resected esophageal squamous cell carcinoma. 9 38
20438666 2010
41
The clinicopathological significance of the expression of Granzyme B in oral squamous cell carcinoma. 9 38
20060355 2010
42
Downregulation of CD9 protein expression is associated with aggressive behavior of oral squamous cell carcinoma. 9 38
20060356 2010
43
FGFR4 polymorphism, TP53 mutation, and their combinations are prognostic factors for oral squamous cell carcinoma. 9 38
20127014 2010
44
Effects of bone morphogenetic protein-2 on proliferation and angiogenesis in oral squamous cell carcinoma. 9 38
20074910 2010
45
Papillary squamous cell carcinoma, not otherwise specified (NOS) of the penis: clinicopathologic features, differential diagnosis, and outcome of 35 cases. 9 38
20061934 2010
46
SNAI1 expression and the mesenchymal phenotype: an immunohistochemical study performed on 46 cases of oral squamous cell carcinoma. 9 38
20181105 2010
47
Clinical significance of the expression of galectin-3 and Pim-1 in laryngeal squamous cell carcinoma. 9 38
20122341 2010
48
Survivin expression in oesophageal squamous cell carcinoma: its prognostic impact and splice variant expression. 9 38
19699104 2010
49
Extraribosomal function of metallopanstimulin-1: reducing paxillin in head and neck squamous cell carcinoma and inhibiting tumor growth. 9 38
19642098 2010
50
Antitumor effects of telomelysin in combination with paclitaxel or cisplatin on head and neck squamous cell carcinoma. 9 38
20043095 2010

Variations for Squamous Cell Carcinoma

ClinVar genetic disease variations for Squamous Cell Carcinoma:

6
# Gene Variation Type Significance SNP ID GRCh37 Pos GRCh38 Pos
1 DDR2 NM_006182.4(DDR2): c.2304T> A (p.Ser768Arg) single nucleotide variant Pathogenic rs267598140 1:162748390-162748390 1:162778600-162778600
2 EGFR ; EGFR-AS1 NM_005228.5(EGFR): c.2428G> A (p.Gly810Ser) single nucleotide variant Likely pathogenic rs121913230 7:55249130-55249130 7:55181437-55181437
3 EGFR ; EGFR-AS1 NM_005228.5(EGFR): c.2429G> A (p.Gly810Asp) single nucleotide variant Likely pathogenic rs121913431 7:55249131-55249131 7:55181438-55181438

Cosmic variations for Squamous Cell Carcinoma:

9 (show top 50) (show all 1195)
# Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA GRCh38 Location Conf
1 COSM44097 TP53 skin,face,carcinoma,basal cell carcinoma c.530C>T p.P177L 17:7675082-7675082 20
2 COSM10660 TP53 skin,hand,carcinoma,squamous cell carcinoma c.818G>A p.R273H 17:7673802-7673802 20
3 COSM43751 TP53 skin,hand,carcinoma,squamous cell carcinoma c.673-1G>A p.? 17:7674291-7674291 20
4 COSM45074 TP53 skin,arm,carcinoma,basal cell carcinoma c.829T>G p.C277G 17:7673791-7673791 20
5 COSM10705 TP53 skin,face,carcinoma,squamous cell carcinoma c.586C>T p.R196* 17:7674945-7674945 20
6 COSM10701 TP53 skin,ear,carcinoma,squamous cell carcinoma c.824G>T p.C275F 17:7673796-7673796 20
7 COSM44225 TP53 skin,arm,carcinoma,squamous cell carcinoma c.859G>A p.E287K 17:7673761-7673761 20
8 COSM44295 TP53 skin,face,carcinoma,basal cell carcinoma c.993+1G>A p.? 17:7673534-7673534 20
9 COSM10939 TP53 skin,face,carcinoma,basal cell carcinoma c.832C>T p.P278S 17:7673788-7673788 20
10 COSM43544 TP53 skin,face,carcinoma,squamous cell carcinoma c.260C>A p.P87Q 17:7676109-7676109 20
11 COSM10656 TP53 skin,arm,carcinoma,squamous cell carcinoma c.742C>T p.R248W 17:7674221-7674221 20
12 COSM44326 TP53 skin,face,carcinoma,squamous cell carcinoma c.706T>C p.Y236H 17:7674257-7674257 20
13 COSM10662 TP53 skin,face,carcinoma,basal cell carcinoma c.743G>A p.R248Q 17:7674220-7674220 20
14 COSM45774 TP53 skin,arm,carcinoma,basal cell carcinoma c.899C>G p.P300R 17:7673721-7673721 20
15 COSM11449 TP53 skin,face,carcinoma,basal cell carcinoma c.388C>T p.L130F 17:7675224-7675224 20
16 COSM44068 TP53 skin,face,carcinoma,basal cell carcinoma c.532C>A p.H178N 17:7675080-7675080 20
17 COSM10654 TP53 skin,face,carcinoma,basal cell carcinoma c.637C>T p.R213* 17:7674894-7674894 20
18 COSM6903965 TP53 skin,ear,carcinoma,squamous cell carcinoma c.988C>T p.L330F 17:7673540-7673540 20
19 COSM45114 TP53 skin,ear,carcinoma,squamous cell carcinoma c.702C>A p.Y234* 17:7674261-7674261 20
20 COSM10726 TP53 skin,face,carcinoma,basal cell carcinoma c.856G>A p.E286K 17:7673764-7673764 20
21 COSM10992 TP53 skin,face,carcinoma,basal cell carcinoma c.844C>G p.R282G 17:7673776-7673776 20
22 COSM43588 TP53 skin,face,carcinoma,squamous cell carcinoma c.740A>C p.N247T 17:7674223-7674223 20
23 COSM45733 TP53 skin,face,carcinoma,basal cell carcinoma c.432G>A p.Q144Q 17:7675180-7675180 20
24 COSM10788 TP53 skin,ear,carcinoma,squamous cell carcinoma c.764T>G p.I255S 17:7674199-7674199 20
25 COSM45830 TP53 skin,face,carcinoma,squamous cell carcinoma c.766A>C p.T256P 17:7674197-7674197 20
26 COSM44832 TP53 skin,arm,carcinoma,squamous cell carcinoma c.1096T>G p.S366A 17:7670613-7670613 20
27 COSM11081 TP53 skin,face,carcinoma,squamous cell carcinoma c.733G>T p.G245C 17:7674230-7674230 20
28 COSM10886 TP53 skin,hand,carcinoma,squamous cell carcinoma c.310C>T p.Q104* 17:7676059-7676059 20
29 COSM12296 TP53 skin,lip,carcinoma,basal cell carcinoma c.292C>T p.P98S 17:7676077-7676077 20
30 COSM43700 TP53 skin,face,carcinoma,basal cell carcinoma c.712T>A p.C238S 17:7674251-7674251 20
31 COSM10733 TP53 skin,face,carcinoma,squamous cell carcinoma c.574C>T p.Q192* 17:7674957-7674957 20
32 COSM44227 TP53 skin,face,carcinoma,basal cell carcinoma c.854A>T p.E285V 17:7673766-7673766 20
33 COSM43651 TP53 skin,face,carcinoma,squamous cell carcinoma c.763A>T p.I255F 17:7674200-7674200 20
34 COSM44435 TP53 skin,face,carcinoma,basal cell carcinoma c.96+1G>A p.? 17:7676381-7676381 20
35 COSM43920 TP53 skin,face,carcinoma,basal cell carcinoma c.680C>T p.S227F 17:7674283-7674283 20
36 COSM43753 TP53 skin,hand,carcinoma,squamous cell carcinoma c.560-1G>A p.? 17:7674972-7674972 20
37 COSM44436 TP53 skin,face,carcinoma,basal cell carcinoma c.375+2T>C p.? 17:7675992-7675992 20
38 COSM43596 TP53 skin,face,carcinoma,basal cell carcinoma c.841G>A p.D281N 17:7673779-7673779 20
39 COSM43537 TP53 skin,hand,carcinoma,squamous cell carcinoma c.565G>A p.A189T 17:7674966-7674966 20
40 COSM11084 TP53 skin,face,carcinoma,basal cell carcinoma c.517G>A p.V173M 17:7675095-7675095 20
41 COSM43742 TP53 skin,face,carcinoma,basal cell carcinoma c.419C>T p.T140I 17:7675193-7675193 20
42 COSM10887 TP53 skin,face,carcinoma,basal cell carcinoma c.833C>G p.P278R 17:7673787-7673787 20
43 COSM44923 TP53 skin,hand,carcinoma,squamous cell carcinoma c.565G>C p.A189P 17:7674966-7674966 20
44 COSM44241 TP53 skin,face,carcinoma,basal cell carcinoma c.592G>T p.E198* 17:7674939-7674939 20
45 COSM46278 TP53 skin,hand,carcinoma,squamous cell carcinoma c.950A>G p.Q317R 17:7673578-7673578 20
46 COSM45145 TP53 skin,hand,carcinoma,squamous cell carcinoma c.590T>C p.V197A 17:7674941-7674941 20
47 COSM44274 TP53 skin,hand,carcinoma,squamous cell carcinoma c.647T>A p.V216E 17:7674884-7674884 20
48 COSM45677 TP53 skin,face,carcinoma,squamous cell carcinoma c.714T>A p.C238* 17:7674249-7674249 20
49 COSM44552 TP53 skin,face,carcinoma,basal cell carcinoma c.509C>T p.T170M 17:7675103-7675103 20
50 COSM44306 TP53 skin,hand,carcinoma,squamous cell carcinoma c.845G>C p.R282P 17:7673775-7673775 20

Copy number variations for Squamous Cell Carcinoma from CNVD:

7 (show top 50) (show all 98)
# CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
1 13821 1 1 7200000 Copy number TP73 Squamous cell cancer
2 25151 1 184907591 184916179 Amplification PTGS2 Squamous cell cancer
3 31938 1 32200000 39600000 Copy number Squamous cell cancer
4 33706 1 47467454 47552406 Amplification STIL Squamous cell cancer
5 42802 10 40300000 135374737 Copy number Squamous cell cancer
6 49690 11 110000000 134452384 Copy number Squamous cell cancer
7 49993 11 112500000 114500000 Copy number IGSF4 Squamous cell cancer
8 57469 11 63400000 77100000 Copy number GSTP1 Squamous cell cancer
9 57471 11 63400000 77100000 Copy number MEN1 Squamous cell cancer
10 61508 12 1 3100000 Gain LOC440123 Squamous cell cancer
11 61509 12 1 3100000 Gain SLC6A12 Squamous cell cancer
12 61511 12 1 3100000 Gain SLC6A13 Squamous cell cancer
13 61529 12 1 35400000 Copy number Squamous cell cancer
14 61608 12 10000000 12600000 Gain CDKN1B Squamous cell cancer
15 61609 12 10000000 12600000 Gain DKFZP434F0318 Squamous cell cancer
16 66096 12 25249446 25295130 Amplification KRAS Squamous cell cancer
17 66577 12 3100000 5300000 Gain LOC399986 Squamous cell cancer
18 66579 12 3100000 5300000 Gain LOC441627 Squamous cell cancer
19 66581 12 3100000 5300000 Gain TSPAN9 Squamous cell cancer
20 75264 13 18400000 72100000 Copy number Squamous cell cancer
21 77032 13 39500000 46200000 Copy number Squamous cell cancer
22 87575 14 74815283 74818665 Amplification FOS Squamous cell cancer
23 93656 15 57100000 61500000 Loss RORA Squamous cell cancer
24 95697 15 79500000 83000000 Loss DNM1DN11-6 Squamous cell cancer
25 95699 15 79500000 83000000 Loss LOC159170 Squamous cell cancer
26 95701 15 79500000 83000000 Loss LOC161527 Squamous cell cancer
27 95703 15 79500000 83000000 Loss LOC388152 Squamous cell cancer
28 95705 15 79500000 83000000 Loss LOC388160 Squamous cell cancer
29 95707 15 79500000 83000000 Loss LOC440300 Squamous cell cancer
30 95709 15 79500000 83000000 Loss LOC440301 Squamous cell cancer
31 97922 16 14700000 16700000 Loss Squamous cell cancer
32 107539 17 15900000 22100000 Loss Squamous cell cancer
33 111141 17 35097918 35138441 Amplification ERBB2 Squamous cell cancer
34 116535 17 6800000 11200000 Copy number Squamous cell cancer
35 122734 18 59800000 76117153 Copy number Squamous cell cancer
36 123838 18 89115825 89123587 Amplification SPP1 Squamous cell cancer
37 124166 19 1 6900000 Gain BSG Squamous cell cancer
38 124167 19 1 6900000 Gain C19orf19 Squamous cell cancer
39 124168 19 1 6900000 Gain C19orf20 Squamous cell cancer
40 124170 19 1 6900000 Gain CDC34 Squamous cell cancer
41 124171 19 1 6900000 Gain GZMM Squamous cell cancer
42 124173 19 1 6900000 Gain MADCAM1 Squamous cell cancer
43 124175 19 1 6900000 Gain SCHC2 Squamous cell cancer
44 135627 2 118600000 122100000 Gain Squamous cell cancer
45 171547 3 169200000 172500000 Gain EVI1 Squamous cell cancer
46 171549 3 169200000 172500000 Gain LOC389174 Squamous cell cancer
47 171551 3 169200000 172500000 Gain MDS1 Squamous cell cancer
48 172148 3 177300000 180600000 Gain KCNMB3 Squamous cell cancer
49 172150 3 177300000 180600000 Gain PIK3CA Squamous cell cancer
50 172227 3 178866310 178952497 Gain PIK3CA Squamous cell cancer

Expression for Squamous Cell Carcinoma

Search GEO for disease gene expression data for Squamous Cell Carcinoma.

Pathways for Squamous Cell Carcinoma

Pathways related to Squamous Cell Carcinoma according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1 9.7 UCA1 HOTAIR

GO Terms for Squamous Cell Carcinoma

Biological processes related to Squamous Cell Carcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 chromatin silencing GO:0006342 8.62 HOTAIR CDKN2B-AS1

Sources for Squamous Cell Carcinoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 TGDB
71 Tocris
72 UMLS
73 UMLS via Orphanet
Content
Loading form....